


## LLY-507

<b>Cat. No.:</b>	HY-19313		
<b>CAS No.:</b>	1793053-37-8		
<b>Molecular Formula:</b>	C <sub>36</sub> H <sub>42</sub> N <sub>6</sub> O		
<b>Molecular Weight:</b>	574.76		
<b>Target:</b>	Histone Methyltransferase		
<b>Pathway:</b>	Epigenetics		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 15 mg/mL (26.10 mM; Need ultrasonic and warming)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM	1.7399 mL	8.6993 mL	17.3986 mL
		5 mM	0.3480 mL	1.7399 mL	3.4797 mL
10 mM		0.1740 mL	0.8699 mL	1.7399 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: 2.5 mg/mL (4.35 mM); Suspended solution; Need ultrasonic</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 2.5 mg/mL (4.35 mM); Clear solution</li> </ol>				

### BIOLOGICAL ACTIVITY

<b>Description</b>	LLY-507 is a potent and selective inhibitor of protein-lysine methyltransferase SMYD2. LLY-507 potently inhibits the ability of SMYD2 to methylate p53 peptide with an IC <sub>50</sub> <15 nM. LLY-507 serves as a valuable chemical probe to aid in the dissection of SMYD2 function in cancer and other biological processes <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	SMYD2 <15 nM (IC <sub>50</sub> )
<b>In Vitro</b>	LLY-507 is >100-fold selective for SMYD2 over 21 other methyltransferases including SMYD3 <sup>[1]</sup> . LLY-507 binds to the substrate channel of SMYD2 and supports the selectivity of its inhibition <sup>[1]</sup> . LLY-507 is able to potently inhibit the methylation of H4 peptide by SMYD2 enzyme with an IC <sub>50</sub> of 31 nM <sup>[1]</sup> .

LLY-507 (0.03-20  $\mu\text{M}$ ; 28 hours) inhibits SMYD2-mediated methylation of p53 Lys<sup>370</sup> in U2OS cells, with an IC<sub>50</sub> of 0.6  $\mu\text{M}$ <sup>[1]</sup>.  
LLY-507 (0-20  $\mu\text{M}$ ; 3-7 days) inhibits the proliferation of several ESCC, HCC, and breast cancer cell lines<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### Cell Proliferation Assay<sup>[1]</sup>

Cell Line:	ESCC, HCC, breast cancer cell lines
Concentration:	0-20 $\mu\text{M}$
Incubation Time:	3 days, 7 days
Result:	Inhibited tumor cell proliferation.

#### Western Blot Analysis<sup>[1]</sup>

Cell Line:	HEK293 cells
Concentration:	0.03 $\mu\text{M}$ , 0.07 $\mu\text{M}$ , 0.15 $\mu\text{M}$ , 0.3 $\mu\text{M}$ , 0.6 $\mu\text{M}$ , 1.25 $\mu\text{M}$ , 2.5 $\mu\text{M}$
Incubation Time:	28 hours
Result:	Inhibited SMYD2-mediated methylation of p53 Lys <sup>370</sup> in cells.

## CUSTOMER VALIDATION

- Exp Mol Med. 2023 May 1.
- Cell Death Dis. 2022 Oct 21;13(10):890.
- Cell Death Dis. 2018 Jan 26;9(2):129.
- Cell Death Discov. 2022 Jun 6;8(1):274.
- Cells. 2022 Apr 8;11(8):1262.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Nguyen H, et al. LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2. J Biol Chem. 2015 May 29;290(22):13641-13653.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA